Equine infectious anemia virus (EIAV) infection of horses provides a valuable model for examining the natural immunological control of lentivirus infection and disease and the mechanisms of protective and enhancing vaccine immunity. We have previously hypothesized that the EIAV envelope (Env) proteins gp90 and gp45 are major determinants of vaccine efficacy, and that the development of protective immunity by attenuated viral vaccines may be associated with the progressive redirection of immune responses from immunodominant, variable Env segments to immunorecessive, conserved Env sequences. Whilst the antibody-neutralization determinants of Env have been defined, there are to date no comprehensive analyses of the lymphoproliferative (T-helper, Th) and cytotoxic T-cell (CTL) epitopes of the EIAV Env proteins. Thus, in the current study, synthetic-peptide methodologies were used to define regions of EIAV Env associated with protective vaccine immunity in a panel of 12 horses inoculated with the attenuated EIAV D9 vaccine and two asymptomatic carrier horses infected experimentally with the virulent EIAV PV strain expressing the same Env protein as the vaccine strain. The results of these studies identified 17 broadly reactive Th peptides and six broadly reactive CTL peptides in the Env proteins of EIAV that were associated with protective immunity. Thus, these data provide for the first time a comprehensive mapping of EIAV Env-specific cellular regions that can be used to examine the development of protective immunity and to evaluate potential cellular immune determinants of protective immunity.
INTRODUCTION
Equine infectious anemia virus (EIAV) is a lentivirus of equids that shares genetic and structural similarities with human immunodeficiency virus type 1 (HIV-1), but causes a unique disease process among the known lentiviruses (Montelaro et al., 1993) . Whilst human and other animal lentiviruses cause progressive degenerative or immunesuppressive disease, EIAV infection of horses is characterized by dynamic recurring disease cycles in the first year of infection. Following this chronic stage of disease, most infected horses progress to a long-term, inapparent carrier state in which disease and virus replication are strictly controlled for the lifespan of the horse. This inapparent state is not attributable to attenuation of the infecting virus, as whole-blood transfers from inapparent carriers can induce disease in naïve recipient horses and immune suppression of inapparent horses can induce a recurrence of disease, indicating the potential virulence of the infecting EIAV (Issel & Coggins, 1979; McGuire et al., 1971; Montelaro et al., 1993) . In addition, inapparent carriers of EIAV appear to be highly resistant to additional exposure to diverse and highly virulent strains of EIAV, suggesting that the immune response in inapparent carriers not only controls the existing infection, but also provides a high level of prophylactic immunity (Montelaro et al., 1993) . Thus, the EIAV system is useful in examining the natural immunological control of a pathogenic lentivirus infection, despite the array of persistence mechanisms employed by these viruses. (Craigo et al., 2005; Hammond et al., 1999; Issel et al., 1992; Li et al., 2003; Lichtenstein et al., 1995; Raabe et al., 1998; Wang et al., 1994) . As observed in similar studies of experimental vaccines in the simian immunodeficiency virus (SIV) and feline immunodeficiency virus systems, live-attenuated EIAV vaccines have to date produced the highest level of vaccine immunity against virulent EIAV challenge (Bogers et al., 2000) . Interestingly, however, these attenuated lentiviral vaccines do not achieve optimum protective immunity until 6 months post-inoculation, indicating a progressive maturation of virus-specific immunity. In addition to the protective immunity observed in EIAV inapparent carriers, the mature immunity elicited by attenuated EIAV vaccines provides a complementary model for defining critical immune correlates of enduring broadly protective vaccine immunity to a lentiviral infection.
Based on a comparison of the quantitative and qualitative properties of lentiviral envelope protein (Env)-specific antibodies, we have defined an association between immature/ non-protective or enhancing and mature/protective virusspecific immunity in the EIAV/horse (Hammond et al., 1999) , SIV/monkey (Clements et al., 1995; Cole et al., 1997) and simian-human immunodeficiency virus/monkey (Cole et al., 1998) vaccine systems. Thus, we propose that lentiviral vaccines must drive this immune maturation sufficiently to achieve protective efficacy. Additionally, we hypothesize that the EIAV Env is a major determinant of vaccine efficacy and that the maturation to protective immunity is associated with a redirection of host immune responses from immunodominant, variable Env domains to relatively immunorecessive, conserved Env domains.
There has been, to date, only limited characterization of cellular and humoral immune responses associated with enduring protective EIAV immunity. Clearance of the acute viraemia typically correlates with the appearance of cytotoxic T lymphocytes (CTLs) (McGuire et al., 1994) and non-neutralizing antibodies Rwambo et al., 1990) . Whilst levels of CTLs fluctuate throughout the disease course, neutralizing antibodies generally do not appear until 2 months post-infection and increase in titre and breadth of specificity during the first year post-infection (Ball et al., 1992; Hammond et al., 1997; Howe et al., 2002; O'Rourke et al., 1988) . Recently, however, Mealey et al. (2005) have shown the presence of neutralizing antibodies immediately after the resolution of acute disease, perhaps suggesting an earlier role for neutralizing antibodies in controlling EIAV replication in experimentally infected horses. During the chronic phase of EIAV infection, there is a high propensity for the selection of antigenic variants of EIAV that are able to temporarily escape the existing neutralizing antibodies directed to Env proteins or CTL responses directed to Gag protein epitopes (Chung et al., 2005; Howe et al., 2002; Hussain et al., 1987; Mealey et al., 2003) . The prevalence of antibody and CTL antigenic variants is consistent with a role for these specific immune responses in controlling EIAV infection. McGuire and colleagues have thoroughly examined the specificity of CTL responses to EIAV Gag and Pol proteins to identify broadly reactive T-helper (Th) and CTL epitopes in these proteins (Chung et al., 2005; Howe et al., 2002; Hussain et al., 1987; Mealey et al., 2003) . However, vaccines based on these broadly reactive T-cell epitopes have failed to elicit protective immunity against EIAV challenge (Fraser et al., 2005) , indicating that immune responses to other viral proteins, such as Env, may be an important component of the establishment of protective immunity to EIAV.
To explain the observed requirement of maturation for protective immunity, we have proposed that the progression towards protection is associated with recognition of conserved immunorecessive epitopes of the Env proteins. A necessary foundation for testing this hypothesis is a detailed characterization of humoral and cellular epitopes in the Env proteins that are recognized during protective immunity. We have previously examined in detail the neutralizing epitopes of EIAV Env proteins and the effects of sequence variation on viral neutralization properties (Ball et al., 1992; Craigo et al., 2002; Howe et al., 2002) . In contrast to the detailed studies of Env neutralization determinants, there have been limited studies of the Th and CTL epitopes of EIAV Env proteins. Thus, in the current study, we have used 12 horses immunized with a highly protective live-attenuated EIAV vaccine and two experimentally infected asymptomatic carrier horses, with the infecting virus strain in both groups of horses expressing identical Env proteins, to elucidate regions of EIAV Env that are broadly recognized by Th and CTL. The results of these studies for the first time provide a comprehensive mapping of Env-specific Th and CTL peptides associated with enduring protective immunity to EIAV and a foundation for determining the effects of Env variation on immune recognition.
METHODS
Experimental subjects. All equine procedures were conducted at the Gluck Equine Research Center of the University of Kentucky according to protocols approved by the University of Kentucky Institutional Animal Care and Use Committee. Twelve horses were vaccinated with the live-attenuated EIAV D9 vaccine (Craigo et al., 2007) . Serological typing of the major histocompatibility complex (MHC) I locus was performed by the University of Kentucky Equine Blood Typing Laboratory using established techniques for the 11 Alocus antigenic specificities of the equine lymphocyte alloantigen (ELA-A) (Table 1) (Bailey, 1980 (Bailey, , 1983 . Direct sequencing of the DRA and DQA MHC II loci was performed by using previously published protocols (Albright-Fraser et al., 1996; Fraser & Bailey, 1998) . Horses C23, C66 and B81 were not MHC II-typed due to lack of cells. After allowing the horses 7 months to establish a mature immune response to the vaccine, blood was drawn from each horse and peripheral blood mononuclear cells (PBMCs) were isolated over a Histopaque gradient. On the following day, the vaccinated horses were challenged intravenously with a reference virulent EIAV PV strain, using a lowdose, multiple-exposure challenge to mimic the predominant natural route of EIAV infection by horsefly bites (Li et al., 2003 Two naïve horses were challenged in parallel with 3610 1 HID (horse infectious dose) as positive infection controls for the EIAV PV lowdose, multiple-exposure challenge. Blood was obtained from these horses at regular intervals, including after each EIAV febrile episode. PBMCs used in these experiments were obtained during asymptomatic stages of infection for these two horses. Five naïve horses were included in the study as uninfected controls. All purified PBMCs were resuspended in autologous serum and 10 % DMSO, and cryopreserved in liquid nitrogen.
Production of synthetic peptides. Eighty-five 20-mer peptides overlapping by 10 residues, representing the entire EIAV UK (GenBank accession no. AF016316) Env, were synthesized in the Biomedical Research Support Facilities Peptide Synthesis Core of the University of Pittsburgh, using an Advanced Chemtech model 396 Omega synthesizer. All peptides were HPLC-purified and confirmed by mass spectrometry. The peptides were dissolved at 2 mg ml 21 in 100 % DMSO and stored at 280 uC until further use. Pools of nine to ten peptides were constructed in a standard matrix such that each peptide was represented in two pools. The pools were used to stimulate PBMCs from the vaccinated and control horses in lymphoproliferation assays and to pulse target cells for chromiumrelease assays. The design of the matrix was such that reactive peptides were indicated by a proliferative or a cytolytic response to the two distinct pools containing the peptide. Reactive peptides were then assayed individually to determine their reactivity in the separate assays (Roederer & Koup, 2003) .
Lymphoproliferation assays. PBMCs from the 12 vaccinated, two infected and five uninfected horses were tested for recognition of EIAV Env peptides in a standard 7 day thymidine-incorporation assay, as described previously (Fraser et al., 2002) with minor modifications. Cryopreserved PBMCs from the vaccinated, challenged and naïve horses were .80 % viable upon thawing and maintained viability throughout the assays, as measured by trypan blue exclusion. PBMCs, at 2610 5 cells per well, were assayed in six replicates in complete RPMI 1640 medium (10 % fetal equine serum, 1 % penicillin/streptomycin, 1 % L-glutamine, 55 mM b-mercaptoethanol).
In initial experiments, we observed relatively high lymphoproliferation backgrounds in PBMCs in the absence of peptide stimulation, apparently resulting from in vitro amplification of vaccine or challenge virus infection in the cultured cells. The addition of AZT (5 mM; Sigma) to the PBMCs upon plating, and its replenishment every 2 days, abrogated virus production and eliminated the observed background lymphoproliferation (data not shown). Cell-viability assays with trypan blue exclusion and MTT (Roche) staining indicated there were no deleterious effects of AZT on PBMC viability. Pokeweed mitogen (PWM) and acetone-extracted EIAV (AE-EIAV) were used as positive proliferative controls throughout the assays at 2.5 and 10 mg ml 21 , respectively. The peptide pools were used at 20 mg ml 21 and individual peptides were used at 10 mg ml 21 . DMSO was added to the medium-control wells to match the DMSO concentration in the peptide wells. The PBMCs were incubated with PWM for 48 h, AE-EIAV for 4 days and the peptides for 6 days prior to labelling with 0.75 mCi (27.75 kBq) [ Challenged horses were infected with EIAV PV and PBMCs were obtained 13 months post-challenge. DPWM and AE-EIAV were used to stimulate cells in the thymidine-incorporation assay. Stimulation indices are reported as the mean±SD. dA pool of gp90 peptides was used to pulse target cells in the chromium-release assay. Specific lysis is reported as the mean±SD. §Horses were ELA-A-typed at the University of Kentucky Equine Blood Typing Laboratory to establish the heterogeneity of the group. ||There were not sufficient PBMCs to determine the haplotype.
Reactive peptides were defined as having .2.5 SI in .50 % of the horses and a P value ,0.05 in the Wilcoxon ranked sums test.
MHC-blocking assay. To determine the MHC specificity of the observed peptide-specific lymphoproliferation, a blocking assay was performed by using anti-equine MHC I (H58A) and MHC II (EqT2) antibodies (VMRD). Preliminary blocking assays showed the optimal antibody concentration for MHC I and MHC II to be 10 mg ml 21 . The optimal concentration for the IgG control was 5 mg ml 21 . The antibodies were incubated with PBMCs (2610 6 cells ml
21
) for 1 h at 37 uC, 5 % CO 2 , before stimulation with peptides at 20 mg ml 21 . After 1 h peptide stimulation in the presence of antibody, the cells were washed three times with 16 PBS/1 % horse serum (HS) and resuspended in 200 ml RPMI complete medium. A standard 7 day thymidine-incorporation assay was then performed as described above. Proliferation was considered to be MHC II-restricted when the SI of the MHC II antibody-treated PBMCs was decreased by .50 % compared with the SI of PBMCs treated with IgG or MHC I antibodies. As MHC II molecules present peptides to CD4 Th cells, it can be inferred that MHC II-restricted peptides cause Th proliferation.
CTL assays. Standard chromium-release assays previously employed for the identification of EIAV CTL epitopes in Gag and Pol were used for these studies, with minor modifications (Hammond et al., 1998; McGuire et al., 1994 McGuire et al., , 1997 Ridgely et al., 2003; Zhang et al., 1998) . PBMCs from the vaccinated or infected horses were expanded in vivo for 7-10 days with either 2.5 mg PWM ml 21 or 10 mg gradientpurified EIAV ml 21 in complete RPMI medium supplemented with 20 U recombinant human interleukin-2 (Hoffmann-La Roche Inc.). After expansion, the PWM-stimulated cells were labelled with 100 mCi (3.7 MBq) 51 Cr (Na 51 CrO) (MP) for 1 h at 37 uC, 5 % CO 2 . Cells were washed four times with 16 PBS/1 % HS and 30 000 cells per well were plated prior to peptide pulsing. Peptide pools were used at a final concentration of 20 mg ml 21 and individual peptides were used at a final concentration of 10 mg ml 21 . The target cells were pulsed for 1 h at 37 uC, 5 % CO 2 . EIAV-stimulated cells were used as effector cells at a 20 : 1 effector : target cell ratio. After the effector cell addition, the cells were incubated for 12-16 h prior to being harvested. Following this incubation, 25 ml cell supernatant was added to 175 ml OptiPhase SuperMix scintillation fluid (Perkin Elmer) Cr release by NP-402spontaneous 51 Cr release)5specific lysis (%). Reactive peptides were defined as causing .10 % specific lysis in .50 % of the reactive horses and to have a P value of ,0.05 in the Mann-Whitney test.
RESULTS

Experimental subjects
The 12 vaccinated horses were subjects of a vaccine trial to test the efficacy of an attenuated vaccine strain, EIAV D9 , containing an engineered 9 bp deletion and two termination codons in the viral S2 gene. Each vaccinated horse seroconverted by 35 days post-infection, and Env-specific serological assays performed on longitudinal serum samples confirmed the establishment of mature immune responses to the vaccine strain of virus by 6 months post-infection (Craigo et al., 2007) . Before the horses were challenged with the reference virulent EIAV PV strain, whole blood was drawn and PBMCs were isolated for use in cellular immune assays. All 12 horses were protected from virulent virus challenge, as evidenced by lack of equine infectious anaemia signs and detectable challenge virus in plasma. Two naïve horses were infected experimentally with EIAV PV to serve as infection and virulence controls for the EIAV PV challenge. PBMCs from these EIAV PV -infected horses were isolated after at least 6 months post-infection, when mature EIAV Envspecific immune responses were documented. PBMCs from five naïve horses were included in the lymphoproliferation assays to establish appropriate background levels.
Proliferation in response to the synthetic peptide pools
Preliminary proliferation assays were performed by using PWM or AE-EIAV as stimulants in a standard thymidineincorporation lymphoproliferation assay. All of the horses responded well to PWM, with SI values of .50 (Table 1) . In response to AE-EIAV, all horses displayed a positive proliferation with SI values ranging from 3 to 140, presumably reflecting the variation in virus-specific immune responses among this outbred population of horses (Table 1) . Proliferation in response to PWM and AE-EIAV demonstrated that the PBMCs maintained proliferative capabilities following cryopreservation and thawing. Based on these preliminary observations, PWM and AE-EIAV were used as positive controls for lymphoproliferation in parallel assays to the peptide stimulations.
An inclusive scan of all potential Th peptides was conducted by using a peptide-matrix strategy. Eighty-five peptides (20-mers overlapping by 10 aa), encompassing the EIAV UK Env proteins gp90 (SU) and gp45 (TM), were synthesized and used in pools of nine to ten peptides (Fig. 1a) to stimulate PBMCs from the vaccinated and infected horses in a standard thymidine-incorporation assay and also to label target cells for the chromium-release assay. Fig. 1(b) is a representative graph of the matrix results for the lymphoproliferation assay. An SI of .1.0 was used as the cutoff for determining positive proliferation. Two independent assays were conducted on PBMCs from each horse for a total of 28 assays. If a peptide was identified as positive (SI .1) in eight of the 28 assays (approx. 30 %), the peptide was subsequently tested individually to determine peptide-specific proliferative properties (Table 2 ). Based on these criteria, 21 peptides were identified and tested individually (Table 2 ). An additional five peptides were also chosen (23, 60, 73, 74 and 77) because the corresponding peptide pools produced high SI values in PBMCs from several horses, but not in the minimum of eight horses.
Peptide-specific lymphoproliferation
To clearly delineate broadly reactive peptides from nonreactive peptides, the 26 peptides identified from the peptide-matrix assays were used to stimulate the PBMCs from the same panel of vaccinated and infected horses. Background proliferation in response to these peptides was established by stimulating PBMCs from five naïve horses with the 26 peptides. The mean background SI was ¡0.9. We defined a reactive peptide as (i) having an SI of .2.5 (greater than two times the background) in seven of the 14 horses and (ii) having a P value of ,0.05 in the Wilcoxon ranked sums test.
Overall, the PBMCs from the vaccinated and infected horses proliferated in response to a variety of peptides (Fig.  2 ). Of the 26 tested peptides, 23 peptides were positive for proliferation in seven of the 14 horses (Fig. 3a) . Only peptides 17, 48 and 58 did not cause proliferation in 50 % of the horses and were therefore not considered reactive. For the 23 peptides that were positive for proliferation in ¢50 % of the horses, the Wilcoxon ranked sums test was used to establish the statistical significance of the SI values. This test takes into consideration the number of positive events and also the magnitude of stimulation. Ranks 1, 2 and 3 were defined as SI values of 2.5-5, 5-7.5 and .7.5, respectively (Fig. 2) . All 23 peptides that caused stimulation in seven of the 14 horses also had P values of ,0.05 and were thus considered to be reactive (Fig. 3a) .
T-cell specificity of peptide-specific lymphoproliferation
As Th cells recognize peptides presented by MHC II receptors, blocking assays were performed to determine whether the peptides are CD4-dependent. Horse D64 was chosen for the depletion assay because PBMCs from this horse responded well in the previous proliferation assays. Monoclonal antibodies specific for MHC I or MHC II antigens or control IgG were incubated with the cells prior to stimulation with the peptides. A standard 7 day proliferation assay with [ 3 H]thymidine was then performed to determine the effects of the antibodies on peptide stimulation. A 50 % decrease in SI of the cells incubated with the MHC II-specific antibody compared with the SI of cells incubated with the MHC I-specific or control IgG antibody indicated that the peptide was MHC II-restricted, indicating the peptide is CD4-dependent. Fourteen of the 23 peptides were determined to be CD4-restricted with this assay (Fig. 3b) . Five of the peptides demonstrated a pattern that indicated that both CD4 and CD8 cells were proliferating in response to those peptides. Peptides 7, 60, 66, 68 and 77 all decreased in SI when MHC I or MHC II antibodies were used. Further studies are needed to verify the results. Peptides 11, 19, 76 and 83 failed to produce significant stimulation in this assay; therefore, we were unable to determine the CD4/CD8 restriction of these peptides (Fig. 3b) .
Cytolytic response to the synthetic peptide pools
Preliminary CTL assays were conducted to determine the cytolytic capabilities of the PBMCs from the panel of vaccinated and infected horses against a pool of sequential Env 20-mer peptides representing the entire gp90 protein sequence. PBMCs from the 12 vaccinated horses displayed cytolytic activity to the Env peptide pool, with specific lysis values ranging from 0 to 30 % ( Table 1) . The PBMC samples from the two infected horses failed to display significant CTL activity against the Env peptide pool at the 6 month post-infection time point.
To identify reactive CTL peptides, the Env peptide-pool matrix was again utilized to screen CTL activity of PBMCs from four of the vaccinated horses. Fig. 1(c) is a representative graph of the matrix results for the CTL assay. The cutoff for a positive cytolytic response was set at 10 % specific lysis and each peptide had to cause lysis in all four assays to be tested individually. With these criteria, 20 peptides were chosen for further analysis as individual peptides (Table 2) . Additionally, peptides 50, 52 and 54 DNumber of times that a peptide was indicated in the cellular assays using the matrix pools. dFor the proliferation assay, a peptide had to be indicated eight or more times (in bold) to be considered for individual analysis. §For the CTL assay, a peptide had to be indicated four times (in bold) to be considered for individual analysis. (Table 2) were assayed in a standard thymidine-incorporation assay to stimulate PBMCs isolated from the 14 horses. A proliferative response to the individual peptides is defined as an SI of .2.5. Graphs show means of three individual assays. Ranks 1, 2 and 3 were defined as an SI of 2.5-5, 5-7.5 and .7.5, respectively.
were chosen because they caused high specific lysis in three of the four CTL assays.
Peptide-specific CTL responses
To determine which peptides were recognized by CTL cells, the 23 peptides identified with the peptide matrix were tested individually in chromium-release assays (Fig. 4) . Of the 12 vaccinated-horse PBMC samples, eight had clear CTL activity against individual envelope peptides. PBMCs from horses C15, 266 and C9 did not have detectable CTLs to the individual peptides at the day of challenge time point and were therefore not used to determine which peptides were reactive. Due to insufficient B61 PBMCs, this horse was also excluded from determining reactive peptides. Specific lysis of PBMCs from untreated and non-reactive horses was typically ,2.0 %, so a 10 % specific lysis cutoff was set for determining which peptides were positive.
The eight horses that responded to the peptides were used to determine which peptides were reactive. For a peptide to be considered reactive, it had to (i) cause 10 % specific lysis in four of the eight responder horses and (ii) have a P value of ,0.05 in the Mann-Whitney test. Of the 23 peptides tested, only seven peptides (5, 9, 17, 23, 27, 50 and 52) caused .10 % specific lysis in four or more of the reactive horses (Fig. 5) . The remaining 16 peptides had ,5 % specific lysis in this cohort of horses. The Mann-Whitney test was used to determine the significance of the specific lysis in the responder horses compared with non-responder horses. Peptides 5, 9, 17, 23, 27, 50 and 52 had P values of ,0.05 (Fig. 5 ) and were subsequently considered to be reactive. Although peptide 28 did have a P value of ,0.05, (Table 2) , were used to assay cytolytic activity of PBMCs from the 12 vaccinated horses in a standard chromium-release assay. A specific lysis of .10 % was considered positive. Graphs show means of three individual assays. *Horses that were used as non-reactive for determining broadly reactive peptides.
it was not considered reactive because only three horses responded to that peptide.
DISCUSSION
The goal of the current study was to use synthetic-peptide methodologies to characterize in detail the specificity of EIAV Env-specific cellular immune responses associated with the protective immunity produced in horses inoculated with an attenuated viral vaccine (12 horses) and in asymptomatic carrier horses (two horses). The results of these comprehensive analyses reveal, for the first time, the overall specificity of Th and CTL responses to EIAV Env that are recognized in horses with protective immunity. These data provide a necessary foundation to examine the evolution of cellular immune responses associated with the progressive maturation of host immunity to a protective stage, to evaluate the role of specific cellular epitopes in the control of EIAV infection and to evaluate experimental Env-based vaccines designed to optimize the immunogenicity of these reactive cellular immune epitopes. In this regard, these studies will provide an important complement to similar studies by McGuire and colleagues that have focused on the nature and protective role of cellular immune responses to EIAV Gag proteins (Chung et al., 2005; Fraser et al., 2002 Fraser et al., , 2005 Mealey et al., 2003 Mealey et al., , 2005 .
For a peptide to be considered broadly reactive, the peptide must be presented by the majority of expressed MHC alleles. Two MHC II loci, which present peptides to Th cells, were typed in this study, and nine of the 11 typed horses had distinct DRA/DQA combinations. C9 and C16 both shared DRA*101/DRA*301 and DQA*301/ DQA*1301, but still differed in their proliferative response to the individual peptides. Therefore, it can be reasoned that they differ at another MHC II locus. Allelic restriction at the less polymorphic DRA allele is not evident with the 23 reactive peptides. At the more polymorphic DQA allele, seven different haplotypes were observed. The dominant allele of the horses typed was DQA*301, with six of the 11 horses expressing that allele. None of the 23 reactive peptides appear to be DQA*301-restricted, as horses with and without DQA*301 reacted to the same peptides. Peptides 29, 68 and 74 appear not to be presented by DQA*301, but seem to be widely presented by the remaining alleles. The next dominant allele was DQA*1301, which was expressed in four of the 11 horses typed. Peptides 76 and 83 are the only two peptides excluded from Th recognition in animals expressing DQA*1301. On closer examination, it is found that only horses with DQA*301, 401 and 501 can recognize peptide 76 and horses expressing DQA*101, 401 and 701 can recognize peptide 83. With fewer than half the expressed DQA alleles recognizing these two peptides, they are not broadly reactive. Whilst peptides 79 and 81 are not presented by the dominant DQA*301 and DQA*1301 alleles, they are considered to be broadly reactive because they seem to be presented by the remaining five alleles. Peptides 7, 9, 11, 19, 23, 25, 27, 35, 60, 66, 70 and 77 appear to be presented by four or more (.50 %) of the DQA alleles and are thereby broadly reactive. Of the 23 identified reactive peptides, it appears that 17 are broadly reactive across a majority of DQA haplotypes (Fig. 6) . Reactive CTL peptides were identified by using a panel of eight vaccinated horses that demonstrated detectable levels of CTL activity. The remaining three non-responding horses were used to establish the background specific lysis for the peptides. *Individual horses were positive for the peptide if the peptide caused specific lysis of .10 %. 3P value was determined by using the Mann-Whitney test. 4Reactive peptides were defined by two criteria: (i) a peptide causing significant specific lysis in four of the eight reactive horses and (ii) a peptide having a P value of ,0.05 in the Mann-Whitney test.
CTL cells recognize peptides presented by MHC I molecules. Only the ELA-A locus has been defined in horses and it is less polymorphic than its human counterpart. The lack of defined ELA-A types may be due to the serological reagents used in the typing process (Chung et al., 2003) . Additionally, there are problems with serological typing, such as allele mismatching. It was reported that target cells from one horse with an ELA-A5 haplotype were not lysed by memory CTLs from another horse with an ELA-A5 haplotype, indicating that the serological reagents used for haplotyping can recognize more alleles non-specifically than thought originally (Zhang et al., 1998) . Until a more discriminating MHC I typing procedure is developed, we cannot definitively assign ELA-A allelic restriction to the defined peptides. It does appear that peptide 50 may not be broadly reactive, in that only one horse without the A2 allele recognizes that peptide. The remaining six peptides are recognized by a range of diverse ELA-A types and can therefore be considered broadly reactive (Fig. 6 ).
Of the 17 broadly reactive Th peptides, nine were located in the gp90 protein and eight in the gp45 protein. gp90, which is the more variable portion of Env, has eight defined variable domains that are assumed to occupy the outer exposed loops on a three-dimensional structure of the protein, like the HIV-1 gp120 protein (Leroux et al., 1997) .
Of the nine broadly reactive Th peptides from the gp90 sequence, four are located in these variable domains (Fig.  6a) . Peptide 19 is in V3, peptide 23 is in V4 and peptides 27 and 29 are both in V5. Only two of the five CTL peptides in this protein are contained in variable domains; peptide 23 is located in the V4 domain and peptide 27 in the V5 domain. The principal neutralization domain (PND), along with other major neutralization-antibody determinants (V4 and V5), are located in the variable loops of gp90. These antibody determinants have considerable overlap with Th and/or CTL peptides. The remaining Th and CTL peptides are in more conserved regions of gp90 that are shielded by the variable loops and are perceived to be immunorecessive.
There are no predetermined variable domains in the gp45 protein, but it is accepted that the cytoplasmic tail is more conserved than the ectodomain. Only one Th peptide (peptide 60) is found in the ectodomain, along with the only CTL peptide of this protein (peptide 52). The remaining seven Th peptides are found in the putative intracytoplasmic tail (Fig. 6b) .
Lentiviral Env proteins are some of the most heavily glycosylated proteins characterized to date. The role of Nlinked glycosylation in antigen presentation has yet to be established. The EIAV gp90 protein has 18 predicted Nlinked glycosylation sites, yet the majority of the identified broadly reactive Th and CTL peptides lack potential glycosylation sites. Additionally, gp45 contains four potential N-linked glycosylation sites and none of them are included in the identified cellular peptides. These data are consistent with the concept that lentiviruses sequester glycosylated Env sequences from cellular recognition, as observed for the SIV Env protein (Sarkar et al., 2002) .
With the current characterization of Th and CTL peptides of EIAV gp90 and gp45 associated with protective immunity, we now have the necessary foundation to examine the evolution of these cellular immune responses during maturation to protective immunity and to evaluate these peptides as correlates of protective vaccine immunity.
